Sanofi Logo
CAD Logo

RESOURCES

Time to talk about your comeback from CAD with ENJAYMO
Whether you're starting ENJAYMO or considering treatment, here are some resources to help you get the answers you need.
HOW MUCH ARE YOU IMPACTED BY FATIGUE?
People living with CAD may feel the impact of chronic fatigue caused by anemia in a variety of ways, including affecting their physical health and daily routine.
Use the sliders below to explore the impact of fatigue with our calculator.*
On average, how many days (0-7) per week are you impacted by fatigue in the following areas:
How many days do you have trouble staying awake during the day?
How many days do you struggle to carry out everyday or routine activities?
How many days does fatigue impact your ability to start a new task?
How many days are you too fatigued to finish a task?
How many days do you need someone's help to complete your usual activities because of your fatigue?
Based on your answers, fatigue affects you 0 out of 7 days per week on average.
Your Fatigue Time
1
2
3
4
5
6
7
0 OUT OF 7 DAYS WITH FATIGUE
That's equivalent to:
-
DAYS A MONTH
-
DAYS A YEAR
*This calculator is provided for self-reflection and is not a diagnostic tool. Your healthcare professional is the best source of information regarding your health. Please consult your healthcare professional if you have any questions about your health or treatment.
HOW MUCH TIME DOES INFUSING WITH ENJAYMO TAKE?
ENJAYMO is given as an intravenous (IV) infusion weekly for the first 2 weeks, and then every 2 weeks thereafter.
Infusion with ENJAYMO usually takes 1 to 2 hours. After your first infusion, you will be monitored for up to 2 hours for possible infusion or allergic reactions. After all future infusions, you will be monitored for 1 hour. After being initiated on ENJAYMO, your infusions occur 1 day every 2 weeks**
1 DAY EVERY 2 WEEKS
AFTER INITIATION ON ENJAYMO
Following initiation, infusions should occur:
~2
DAYS A MONTH
26
DAYS A YEAR
**This time may vary between individuals and does not account for outside factors such as travel to and from infusion facilities, preparation for treatment, monitoring, additional labs, or doctor’s visits due to side effects of treatment. Be sure to speak with your healthcare provider with any questions you may have regarding infusions.
ADDRESSING THE IMPACT OF CAD WITH ENJAYMO
If your body destroys red blood cells faster than it can replace them, it can lead to anemia. It’s this chronic anemia that causes fatigue in CAD patients. ENJAYMO addresses the source of fatigue by helping stop hemolysis in its tracks.
SIGNIFICANT IMPROVEMENT IN FATIGUE
Patients on ENJAYMO were asked about the impact of fatigue on a scale of 0 (not at all) to 4 (very much so) for a total of 52 points. This 13-item survey (FACIT) included questions like:
How fatigued they felt
Frustration because of tiredness
Need to take a nap to get through the day
How weak and tired they felt
Ability to do usual activities
In the clinical trial, patients on ENJAYMO had an average 11-point improvement from baseline (improving from an average baseline score of 31.67 points to an average score at treatment assessment of 42.5 points) vs a 2-point improvement in patients on placebo. Higher scores on the survey meant a person felt less fatigue.
Doctor Discussion Guide
Use this guide to have a productive conversation with your doctor or healthcare team to see if ENJAYMO is right for you.
Your guide to enjaymo
Find out more information about CAD and ENJAYMO to help you get started.
Blood lab card
Because CAD is associated with colder temperatures, it's extremely important that your blood stays warm. Use this card to help ensure that healthcare providers and support staff are handling your blood properly.
Blood Test Tracker
This useful tracker will help you stay on top of your blood test results and any changes you feel in your body. Knowing what to monitor and what your levels are is important for both you and your doctor when managing CAD.
ENJAYMO ENROLLMENT FORM
If you've been prescribed ENJAYMO, work with your doctor to complete the ENJAYMO Patient Solutions Enrollment Form to get started with support services that are available to you.
Connecting with the community
Various advocacy groups exist that offer support for patients living with CAD and the people involved in their care. A few examples are:
There are a number of organizations dedicated to providing information and support to people living with CAD and other rare disorders. This listing is provided as a resource only and does not constitute an endorsement by Sanofi of any particular organization or its programming. Additional resources on this topic may be available and should be investigated. Sanofi does not review or control the content of non-Sanofi websites.
ATTEND AN Educational ENJAYMO EVENT
Find free in-person and online educational events to learn more about CAD and ENJAYMO.
INDICATION
ENJAYMO® is a prescription medicine used to treat the breakdown of red blood cells (hemolysis) in adults with cold agglutinin disease (CAD).

It is not known if ENJAYMO is safe and effective in children.
IMPORTANT SAFETY INFORMATION
Do not receive ENJAYMO if you are allergic to sutimlimab-jome or any of the ingredients in ENJAYMO.
ENJAYMO can cause serious side effects, including:
Serious Infections: ENJAYMO is a prescription medicine that affects your immune system. ENJAYMO may lower the ability of your immune system to fight infections. ENJAYMO increases your chance of getting serious infections including those caused by encapsulated bacteria, including Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae type B. These serious infections may quickly become life-threatening or cause death if not recognized and treated early.
You must complete or be up to date with the vaccines against Streptococcus pneumoniae and Neisseria meningitidis at least 2 weeks before your first dose of ENJAYMO.
If your healthcare provider decides that urgent treatment with ENJAYMO is needed, you should receive vaccinations as soon as possible.
If you have been vaccinated against these bacteria in the past, you might need additional vaccines before starting ENJAYMO. Your healthcare provider will decide if you need additional vaccines.
Vaccines do not prevent all infections caused by encapsulated bacteria. Call your healthcare provider or get emergency medical care right away if you get any of these signs and symptoms of a serious infection:
fever with or without shivers or chills
fever and a rash
fever with chest pain and cough
fever with breathlessness or fast breathing
fever with high heart rate
headache with nausea or vomiting
headache and fever
headache with stiff neck or stiff back
confusion
body aches with flu-like symptoms
clammy skin
eyes sensitive to light
Infusion-related reactions: Treatment with ENJAYMO may cause infusion-related reactions, including allergic reactions that may be serious or life-threatening. Your healthcare provider may slow down or stop your ENJAYMO infusion if you have an infusion-related reaction and will treat your symptoms if needed. Tell your healthcare provider right away if you develop symptoms during your ENJAYMO infusion that may mean you are having an infusion-related reaction, including:
shortness of breath
nausea
dizziness
decrease in blood pressure
injection site reaction
rash
chest discomfort
flushing
itchy skin
rapid heartbeat
headache
Risk of autoimmune disease: ENJAYMO may increase your risk for developing an autoimmune disease such as systemic lupus erythematosus (SLE). Tell your healthcare provider and get medical help if you develop any symptoms of SLE, including:
joint pain or swelling
rash on the cheeks and nose
unexplained fever
If you have CAD and you stop receiving ENJAYMO, your healthcare provider should monitor you closely for the return of your symptoms after you stop ENJAYMO. Stopping ENJAYMO may cause the breakdown of your red blood cells due to CAD return. Symptoms or problems that can happen due to red blood cell breakdown include:
Tiredness
Rapid heart rate
Shortness of breath
Blood in your urine or dark urine
The most common side effects of ENJAYMO include:
increase in blood pressure
joint pain
dizziness
urinary tract infection
headache
feeling tired or weak
respiratory tract infection
nausea
cough
bacterial infection
runny nose
swelling in lower legs or hands
bluish color to the lips and skin
changes in color or sensation in the fingers and toes (Raynaud's phenomenon)
These are not all the possible side effects of ENJAYMO. Call your doctor for medical advice about side effects.
Before receiving ENJAYMO, tell your healthcare provider about all of your medical conditions, including if you:
have a fever or infection, including a history of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C.
have an autoimmune disease such as systemic lupus erythematosus (SLE), also known as lupus.
are pregnant or plan to become pregnant. It is not known if ENJAYMO will harm your unborn baby.
are breastfeeding or plan to breastfeed. It is not known if ENJAYMO passes into your breast milk.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.
INDICATION
ENJAYMO® is a prescription medicine used to treat the breakdown of red blood cells (hemolysis) in adults with cold agglutinin disease (CAD).

It is not known if ENJAYMO is safe and effective in children.
Back to the top